Stock RNXT RENOVORX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases RenovoRx, Inc.

Equities

RNXT

US75989R1077

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-10 pm EDT 		5-day change 1st Jan Change
1.45 USD +7.81% Intraday chart for RenovoRx, Inc. +18.85% -36.68%
Apr. 16 RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting CI
Apr. 15 RenovoRx, Inc. announced that it has received $11.136652 million in funding CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
BU
RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement
AQ
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
BU
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech
AQ
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
BU
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
BU
RenovoRx Announces $11.1 Million at Market Private Placement
BU
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
AQ
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
BU
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
BU
RenovoRx Highlights Key Leadership Promotions
AQ
RenovoRx Highlights Key Leadership Promotions
BU
RenovoRx CEO Issues Letter to Shareholders
BU
RenovoRx Closes $6.1 Million Private Placement
BU
RenovoRx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
AQ
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
BU
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
BU
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
BU
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
BU
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNXT Stock
  4. News RenovoRx, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW